Eli Lilly and Company (NYSE:LLY) Stock Price Down 1.2% – Here’s What Happened

Posted by Brian Himes on Jun 18th, 2026

Eli Lilly and Company logo Eli Lilly and Company (NYSE:LLY – Get Free Report)’s stock price was down 1.2% during mid-day trading on Thursday . The stock traded as low as $1,088.66 and last traded at $1,098.78. Approximately 4,423,300 shares were traded during trading, an increase of 38% from the average daily volume of 3,202,614 shares. The stock had previously closed at $1,112.00.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Lilly’s pipeline remains in focus after updates on multiple clinical programs, including completion of its Mevidalen Alzheimer’s trial and retatrutide study, which keep investors watching for next-stage data and future commercial opportunities.
Positive Sentiment: Lilly continues to expand its AI-driven drug discovery platform, Lilly TuneLab, through new collaborations with Charles River Laboratories, Chai Discovery, and Axcelead DDP, reinforcing the company’s innovation story and potential long-term R&D productivity. Article Title
Positive Sentiment: Investor interest is also being supported by commentary that Eli Lilly remains a leading growth name in healthcare, with articles highlighting its GLP-1 momentum and strong earnings growth outlook.
Neutral Sentiment: Cathie Wood reportedly bought Eli Lilly shares, which may be seen as a sentiment boost, but this is not a direct business catalyst.
Negative Sentiment: Competition in obesity drugs is intensifying, with Pfizer aiming to take share from Lilly and Novo Nordisk through monthly injectables and oral programs, potentially pressuring Lilly’s long-term dominance in the category.
Negative Sentiment: Lilly also faces Europe-related headwinds after halving its planned Germany investment, citing drug pricing reforms that could weigh on future international expansion and capital allocation.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Barclays boosted their target price on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, May 21st. Rothschild & Co Redburn boosted their price target on Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. The Goldman Sachs Group reissued a “buy” rating and issued a $1,283.00 price target on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Finally, Berenberg Bank increased their price objective on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a report on Thursday, February 19th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,227.74.

View Our Latest Analysis on Eli Lilly and Company

Eli Lilly and Company Price Performance

The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock has a market capitalization of $1.03 trillion, a P/E ratio of 39.03, a PEG ratio of 1.23 and a beta of 0.53. The stock’s fifty day moving average is $1,009.79 and its 200-day moving average is $1,016.67.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same period last year, the company earned $3.34 earnings per share. The business’s revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Institutional Investors Weigh In On Eli Lilly and Company

Large investors have recently added to or reduced their stakes in the stock. 10Elms LLP lifted its stake in shares of Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after buying an additional 10 shares during the last quarter. M.E. Allison & CO. Inc. grew its stake in Eli Lilly and Company by 0.7% in the 4th quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock valued at $1,587,000 after buying an additional 10 shares during the last quarter. Tanager Wealth Management LLP raised its holdings in Eli Lilly and Company by 2.6% in the 4th quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock worth $424,000 after acquiring an additional 10 shares during the period. Morey & Quinn Wealth Partners LLC raised its holdings in Eli Lilly and Company by 1.5% in the 4th quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock worth $710,000 after acquiring an additional 10 shares during the period. Finally, Wealthspan Partners LLC lifted its position in Eli Lilly and Company by 0.5% during the 4th quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock worth $2,268,000 after acquiring an additional 10 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.